Protect nursing home residents from future pandemics

AcleaningcrewwearingprotectiveclothingtakesdisinfectingequipmentintoanursinghomeintheSeattlesuburbsf AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s




leisure time

author：entertainment    Page View：472
Astrazeneca office building -- health policy coverage from STAT
AstraZeneca is suing the Biden administration to stop a new Medicare drug price negotiation program. Adobe

WASHINGTON — AstraZeneca is the sixth drugmaker to pile on a legal challenge to the Biden administration’s drug pricing reform law.

The Medicare drug price negotiation program created in the Inflation Reduction Act is set to kick off in the next week, as officials will release the names of the first 10 medicines that will be selected for the program. Medicines are eligible for selection if they are one of the highest-spend drugs for Medicare, and they have no generic competition.

advertisement

AstraZeneca makes drugs that could be selected for the list, and asked a Delaware district court judge to rule that Medicare acted illegally and that the law is unconstitutional.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： New research sheds light on how often breast cancer is overdiagnosed
Next article： Peter Hotez and the public health issue of online harassment